NKTR

Nektar Therapeutics (NKTR)

Nektar Therapeutics

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:NKTR

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/09/25	16 : 30	PR Newswire (US)	Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024	NASDAQ:NKTR	Nektar Therapeutics
2024/09/03	22 : 00	PR Newswire (US)	Nektar Management to Present at Upcoming Investor Conferences	NASDAQ:NKTR	Nektar Therapeutics
2024/08/21	10 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NKTR	Nektar Therapeutics
2024/08/21	10 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NKTR	Nektar Therapeutics
2024/08/21	10 : 14	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NKTR	Nektar Therapeutics
2024/08/20	05 : 13	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NKTR	Nektar Therapeutics
2024/08/20	05 : 03	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NKTR	Nektar Therapeutics
2024/08/20	04 : 45	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NKTR	Nektar Therapeutics
2024/08/09	05 : 20	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NKTR	Nektar Therapeutics
2024/08/09	05 : 15	PR Newswire (US)	Nektar Therapeutics Reports Second Quarter 2024 Financial Results	NASDAQ:NKTR	Nektar Therapeutics
2024/08/02	07 : 00	PR Newswire (US)	Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets	NASDAQ:NKTR	Nektar Therapeutics
2024/06/15	07 : 02	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NKTR	Nektar Therapeutics
2024/06/15	05 : 11	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NKTR	Nektar Therapeutics
2024/06/12	22 : 30	PR Newswire (US)	Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024	NASDAQ:NKTR	Nektar Therapeutics
2024/06/07	05 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NKTR	Nektar Therapeutics
2024/06/06	13 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:NKTR	Nektar Therapeutics
2024/06/06	06 : 30	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:NKTR	Nektar Therapeutics
2024/05/31	07 : 00	PR Newswire (US)	Nektar Management to Present at Upcoming Investor Conferences	NASDAQ:NKTR	Nektar Therapeutics
2024/05/29	05 : 51	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:NKTR	Nektar Therapeutics
2024/05/21	10 : 14	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NKTR	Nektar Therapeutics
2024/05/21	10 : 13	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NKTR	Nektar Therapeutics
2024/05/21	10 : 12	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NKTR	Nektar Therapeutics
2024/05/18	05 : 25	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NKTR	Nektar Therapeutics
2024/05/18	05 : 22	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NKTR	Nektar Therapeutics
2024/05/18	05 : 14	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NKTR	Nektar Therapeutics
2024/05/14	05 : 36	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NKTR	Nektar Therapeutics
2024/05/10	05 : 20	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NKTR	Nektar Therapeutics
2024/05/10	05 : 15	PR Newswire (US)	Nektar Therapeutics Reports First Quarter 2024 Financial Results	NASDAQ:NKTR	Nektar Therapeutics
2024/05/03	07 : 00	PR Newswire (US)	Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets	NASDAQ:NKTR	Nektar Therapeutics
2024/03/23	03 : 00	PR Newswire (US)	Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference	NASDAQ:NKTR	Nektar Therapeutics